COVID-19 疫苗接种与降低非 COVID-19 住院死亡率相关。
COVID-19 vaccination is associated with reduced non-COVID in-hospital mortality.
机构信息
Department of Medicine (retired), Hadassah University Hospital Jerusalem, Israel.
Clinical Utility Department, Sanz Medical Center, Laniado Hospital, Netanya and School of Public Health, University of Tel Aviv, Israel.
出版信息
Prev Med. 2022 Nov;164:107326. doi: 10.1016/j.ypmed.2022.107326. Epub 2022 Nov 2.
Abstract
We retrieved data on a cohort of medical patients at a regional Israeli hospital. The dependent variable was non-COVID-19 hospital mortality; the independent variables were vaccination status, age, and laboratory data. Serum sodium, age, serum creatinine, and COVID-19 vaccination status were the main independent variables associated with non-COVID-19 mortality. The odds ratio for in-hospital deaths of non-vaccinated patients was 2.01 (1.65-2.44) (unadjusted) and 1.61 (1.29-2.03) after adjustment for the independent variables. This "healthy adherer effect" may confound observational assessments of the clinical efficacy of COVID-19 vaccines.
摘要
我们检索了以色列一家地区医院的一组医疗患者的数据。因变量是非 COVID-19 医院死亡率；自变量是疫苗接种状态、年龄和实验室数据。血清钠、年龄、血清肌酐和 COVID-19 疫苗接种状态是与非 COVID-19 死亡率相关的主要独立变量。未接种疫苗患者住院死亡的优势比为 2.01（1.65-2.44）（未调整），调整独立变量后为 1.61（1.29-2.03）。这种“健康遵医效应”可能会混淆对 COVID-19 疫苗临床疗效的观察性评估。
相似文献
1
COVID-19 vaccination is associated with reduced non-COVID in-hospital mortality.COVID-19 疫苗接种与降低非 COVID-19 住院死亡率相关。
Prev Med. 2022 Nov;164:107326. doi: 10.1016/j.ypmed.2022.107326. Epub 2022 Nov 2.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Variables Associated With COVID-19 Vaccination Among Israeli Adolescents and the Need for Targeted Interventions.与以色列青少年 COVID-19 疫苗接种相关的变量以及需要针对性干预的措施。
Pediatr Infect Dis J. 2022 Nov 1;41(11):927-932. doi: 10.1097/INF.0000000000003664. Epub 2022 Aug 12.
4
Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System.疫苗对法国海外领土内严重 COVID-19 结局的有效性：一项基于国家卫生数据系统的 2 剂接种者与未接种者匹配的队列研究，随访至 2021 年 9 月。
PLoS One. 2022 Sep 9;17(9):e0274309. doi: 10.1371/journal.pone.0274309. eCollection 2022.
5
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.COVID-19 疫苗接种对癌症患者使用 PD-1 抑制剂治疗的影响：一项真实世界研究。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004157.
6
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.在以色列全国范围内使用辉瑞-生物科技公司的 BNT162b2 mRNA COVID-19 疫苗进行疫苗接种运动，以预防感染、住院和死亡：一项回顾性监测研究。
Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22.
7
Vaccine and Psychological Booster: Factors Associated With Older Adults' Compliance to the Booster COVID-19 Vaccine in Israel.疫苗和心理助推器：与以色列老年人遵守 COVID-19 加强疫苗相关的因素。
J Appl Gerontol. 2022 Jul;41(7):1636-1640. doi: 10.1177/07334648221081982. Epub 2022 Apr 5.
8
COVID-19 vaccination during pregnancy: coverage and safety.妊娠期 COVID-19 疫苗接种：覆盖范围和安全性。
Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14. doi: 10.1016/j.ajog.2021.08.007. Epub 2021 Aug 10.
9
Inactivated COVID-19 vaccination does not affect in vitro fertilization outcomes in women.灭活的 COVID-19 疫苗不会影响女性的体外受精结局。
Hum Reprod. 2022 Aug 25;37(9):2054-2062. doi: 10.1093/humrep/deac160.
10
COVID-19 Vaccination, Morbidity, and Mortality During a 12-Month Period in Israel: Can We Maintain a "Herd Immunity" State?以色列12个月期间的新冠疫苗接种、发病率和死亡率：我们能否维持“群体免疫”状态？
Popul Health Manag. 2022 Oct;25(5):684-691. doi: 10.1089/pop.2022.0078. Epub 2022 Jul 25.
引用本文的文献
1
Older hospitalised patients with a chief complaint of weakness and nonspecific presentations are not at risk of adverse health outcomes.以虚弱和非特异性症状为主诉的老年住院患者不存在不良健康结局风险。
J Eval Clin Pract. 2025 Apr;31(3):e14183. doi: 10.1111/jep.14183. Epub 2024 Oct 13.
本文引用的文献
1
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.在全国范围内接种第四剂 BNT162b2 mRNA 新冠疫苗。
N Engl J Med. 2022 Apr 28;386(17):1603-1614. doi: 10.1056/NEJMoa2201688. Epub 2022 Apr 13.
2
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
3
Covid-19 Vaccine Effectiveness in New York State.纽约州的新冠疫苗有效性。
N Engl J Med. 2022 Jan 13;386(2):116-127. doi: 10.1056/NEJMoa2116063. Epub 2021 Dec 1.
4
BNT162b2 Vaccine Booster and Mortality Due to Covid-19.BNT162b2 疫苗加强针与新冠病毒导致的死亡率。
N Engl J Med. 2021 Dec 23;385(26):2413-2420. doi: 10.1056/NEJMoa2115624. Epub 2021 Dec 8.
5
COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021.COVID-19 疫苗接种与非 COVID-19 死亡率风险-2020 年 12 月 14 日至 2021 年 7 月 31 日期间，美国七个综合医疗保健组织。
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520-1524. doi: 10.15585/mmwr.mm7043e2.
6
Covid-19 Vaccine Effectiveness and the Test-Negative Design.新冠病毒疫苗效力与检测阴性设计
N Engl J Med. 2021 Oct 7;385(15):1431-1433. doi: 10.1056/NEJMe2113151. Epub 2021 Sep 8.
7
Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?当前高收入国家的新冠疫苗试验：安慰剂对照试验是否符合伦理道德？
Clin Microbiol Infect. 2021 Nov;27(11):1565-1567. doi: 10.1016/j.cmi.2021.08.005. Epub 2021 Aug 8.
8
Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents.mRNA SARS-CoV-2 疫苗接种后美国养老院居民的不良事件。
Vaccine. 2021 Jun 29;39(29):3844-3851. doi: 10.1016/j.vaccine.2021.05.088. Epub 2021 May 28.
9
Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.新型冠状病毒肺炎疫苗的疗效与安全性：随机临床试验的系统评价与荟萃分析
Vaccines (Basel). 2021 May 6;9(5):467. doi: 10.3390/vaccines9050467.
10
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021.辉瑞-生物科技和莫德纳疫苗对≥65 岁住院成年人 COVID-19 的有效性-美国，2021 年 1 月至 3 月。
MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):674-679. doi: 10.15585/mmwr.mm7018e1.
Zotero 插件